[A]: Heyï¼Œå…³äº'æœ€è¿‘æœ‰å°è¯•ä»€ä¹ˆnew cocktail recipeå—ï¼Ÿ'è¿™ä¸ªè¯é¢˜ï¼Œä½ æ€ä¹ˆæƒ³çš„ï¼Ÿ
[B]:  ä½œä¸ºåŒ»ç–—æ³•å¾‹é¡¾é—®ï¼Œæˆ‘æ›´å…³æ³¨é…’ç²¾å¯¹healthçš„å½±å“å‘¢ã€‚ä¸è¿‡è¯´åˆ°cocktailï¼Œæˆ‘å€’æ˜¯çŸ¥é“ä¸€äº›å…³äºé…’ç²¾é¥®æ–™labelingçš„legal requirements~
[A]: Oh~ é‚£çœŸæ˜¯interestingï¼ğŸ˜Š å…¶å®æˆ‘æœ€è¿‘åœ¨ç ”ç©¶ä¸€æ¬¾ä½é…’ç²¾çš„mocktailï¼Œå®Œå…¨ç¬¦åˆFDAçš„labeling requirementså‘¢ï¼ä½ çŸ¥é“Article 12é‡Œå¯¹é…’ç²¾å«é‡çš„è§„å®šå—ï¼Ÿ
[B]:  è®©æˆ‘æƒ³æƒ³... Article 12ç¡®å®è§„å®šäº†é…’ç²¾å«é‡ä½äº0.5%æ‰èƒ½æ ‡æ³¨ä¸ºnon-alcoholic beverageã€‚ä¸è¿‡ä»medicalçš„è§’åº¦æ¥çœ‹ï¼Œå³ä½¿æ˜¯low-alcohol drinksä¹Ÿè¦æ³¨æ„consumption frequencyå“¦~
[A]: Exactlyï¼ğŸ¤” è€Œä¸”æ ¹æ®æœ€æ–°çš„clinical studyï¼Œé•¿æœŸé¥®ç”¨even low-alcoholçš„é¥®å“ä¹Ÿä¼šå¯¹liver functionäº§ç”Ÿå½±å“å‘¢~ è¦ä¸è¦å¬å¬æˆ‘æœ€è¿‘åœ¨medical journalä¸Šè¯»åˆ°çš„findingsï¼Ÿ
[B]:  è¯·è¯´ã€‚ä½œä¸ºlegal advisorï¼Œæˆ‘ç‰¹åˆ«å…³æ³¨evidence-basedçš„ç ”ç©¶ã€‚ä¸è¿‡Let me remind youï¼Œä»»ä½•medical claimåœ¨labelä¸Šä½¿ç”¨æ—¶éƒ½éœ€è¦proper clinical trial dataæ¥support~
[A]: Absolutelyï¼ğŸµ è¿™ç¯‡studyå°±é‡‡ç”¨äº†double-blindçš„trial designï¼Œæ ·æœ¬é‡è¾¾åˆ°äº†2000+ participantså‘¢~ ä¸è¿‡è¯´åˆ°labelingï¼Œä½ çŸ¥é“FDAæœ€è¿‘æ›´æ–°çš„guidelinesé‡Œå¯¹health claimsçš„wordingæœ‰å¤šstrictå—ï¼Ÿ
[B]:  å•Šï¼Œ2023å¹´æ›´æ–°çš„guidelineç¡®å®æ›´stringentäº†ã€‚ç°åœ¨è¿'å¯èƒ½'ã€'æœ‰åŠ©äº'è¿™æ ·çš„wordingéƒ½éœ€è¦substantial scientific evidenceæ¥back upã€‚è¯è¯´å›æ¥ï¼Œè¿™ä¸ªresearchçš„p-valueæ˜¯å¤šå°‘ï¼Ÿ
[A]: The p-valueæ˜¯0.003ï¼Œstatistically significantå“¦ï¼ğŸ˜Š ä¸è¿‡ä»legal perspectiveæ¥çœ‹ï¼Œå°±ç®—æ•°æ®å†solidï¼Œåœ¨product packagingä¸Šåšä»»ä½•health claiméƒ½è¿˜æ˜¯è¦ç»è¿‡rigorous review processçš„~ æœ€è¿‘å°±æœ‰ä¸€ä¸ªcaseå› ä¸ºè¿™ç‚¹è¢«FDA warningäº†å‘¢
[B]:  ç¡®å®ï¼Œå»å¹´æˆ‘ä»¬å¾‹æ‰€å°±å¤„ç†è¿‡ç±»ä¼¼çš„litigation caseã€‚ä¼ä¸šä»¥ä¸ºæœ‰research dataå°±ä¸‡äº‹å¤§å‰ï¼Œç»“æœå¿½ç•¥äº†regulatory complianceçš„ç»†èŠ‚ã€‚By the wayï¼Œè¿™ä¸ªstudyçš„peer review statuså¦‚ä½•ï¼Ÿ
[A]: Publishedåœ¨JAMAä¸Šï¼Œimpact factorè¶…é«˜çš„ï¼ğŸ¤“ ä¸è¿‡è¯´åˆ°complianceï¼Œä½ çŸ¥é“EUå’ŒUSåœ¨alcohol labelingæ–¹é¢çš„regulatory differenceså—ï¼Ÿæœ€è¿‘æœ‰ä¸ªclientæ­£åœ¨ä¸ºè¿™ä¸ªheadacheå‘¢~
[B]:  Interesting questionã€‚EUçš„Regulation 1169/2011è¦æ±‚æ›´è¯¦ç»†çš„nutrition labelingï¼Œè€ŒFDAæ›´å…³æ³¨health warning statementsã€‚å»ºè®®ä½ çš„clientåšmarket entryå‰å…ˆconsultä¸“ä¸šçš„regulatory affairs team~
[A]: Totally agreeï¼ğŸµ æˆ‘ä»¬å¾‹æ‰€çš„cross-border practiceå°±ç»å¸¸è¦deal withè¿™ç§regulatory gapå‘¢~ è¦ä¸è¦äº¤æ¢ä¸‹contact infoï¼Ÿè¯´ä¸å®šä»¥åå¯ä»¥collaborate on caseså“¦ï¼ğŸ˜Š
[B]:  å½“ç„¶ï¼Œæˆ‘çš„emailæ˜¯linzhiyuan@medlaw.comã€‚ä¸è¿‡before we proceedï¼Œå»ºè®®å…ˆsignä¸ªNDAï¼Œæ¯•ç«Ÿmedical data confidentialityå¯æ˜¯serious business~
[A]: Smart moveï¼ğŸ¤ æˆ‘è¿™å°±è®©assistant draftä¸€ä»½standard NDA agreementå‘ç»™ä½ review~ é¡ºä¾¿å¯ä»¥shareä¸€äº›æˆ‘ä»¬å¤„ç†è¿‡çš„similar casesçš„redacted versionä½œä¸ºreferenceå“¦ï¼
[B]:  Perfectã€‚Let's schedule a meeting next week to discuss furtherã€‚æˆ‘å‘¨äºŒä¸‹åˆ3ç‚¹æœ‰ä¸ªslotï¼Œå¯ä»¥å®‰æ’ä¸ªvirtual conference callã€‚Bring your legal team along~
[A]: Got itï¼ğŸ“… æˆ‘ä¼šccæˆ‘ä»¬compliance teamçš„leadï¼Œå¥¹specialize in FDA regulationsã€‚Looking forward to our collaboration~ å…ˆå‘ä½ ä¸€ä»½meeting agenda draftå¦‚ä½•ï¼Ÿ
[B]:  è¯·å‘åˆ°æˆ‘çš„emailã€‚Agendaé‡Œè®°å¾—include regulatory framework comparisonå’Œcase study sessionã€‚Ohï¼Œand don't forget to attach thoseredacted case files~ See you next Tuesday!
[A]: Will doï¼ğŸ“§ æˆ‘ä¼šhighlightå‡ ä¸ªkey regulatory pain points~ Have a great weekend aheadï¼ğŸ˜Š å‘¨äºŒè§ï¼
[B]:  Enjoy your weekend tooã€‚Remember to review the latest FDA guidance update before our meeting~ å‘¨äºŒè§ï¼